| P/E (FY) | — | Sales (TTM) | $72.3M |
| Earnings (TTM) | -$6.4M | ROE | −5.10% |
| Net Margin | −8.47% | ROIC | −13.36% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $406.4M | Trading Days | 3921 |
| 52W High | 39.70 |
| 52W Low | 16.90 |
| % Off High | −35.60% |
| YTD | −24.82% | 1Y | 31.13% |
| 3Y | 89.49% | 5Y | −40.05% |
| 10Y | −64.33% | Since incept. (ann.) | −15.87% |
| Ann. Volatility (1Y) | 59.21% | Ann. Volatility (3Y) | 74.85% |
| Sharpe (1Y) | 0.76 | Sharpe (3Y) | 0.63 |
| Max Drawdown (1Y) | −41.48% | Max Drawdown (3Y) | −57.49% |
| Beta (3Y, vs SPY) | 1.13 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | $405.7M | 13.1 |
| EVMN | Evommune, Inc. | $405.2M | — |
| BNTC | Benitec Biopharma Inc. | $408.5M | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $403.9M | 12.5 |
| EOLS | Evolus, Inc. | $409.6M | — |
| LRMR | Larimar Therapeutics, Inc. | $397.9M | — |
| KROS | Keros Therapeutics, Inc. | $381.2M | 4.4 |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $380.5M | — |
| EBS | Emergent BioSolutions Inc. | $377.2M | 7.9 |
| OVID | Ovid Therapeutics Inc. | $440.5M | — |
| PRLD | Prelude Therapeutics Inc | $369.6M | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $448.1M | — |
